Inozyme Pharma Inc. (INZY) Prices 7M Share IPO at $16/Sh

Inozyme Pharma, Inc. (NASDAQ: INZY) today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $16.00 per share, for gross proceeds of $112.0 million, before underwriting discounts and commissions and offering expenses payable by Inozyme. In addition, Inozyme has granted the underwriters an option for a period of 30 days to purchase up to 1,050,000 additional shares of common stock at the initial public offering price, less underwriting discounts and commissions. All shares are being offered and sold by Inozyme.

Inozyme’s common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “INZY” on July 24, 2020. The offering is expected to close on or about July 28, 2020, subject to the satisfaction of customary closing conditions.

BofA Securities, Cowen and Piper Sandler are acting as joint book-running managers for the offering. Wedbush PacGrow is acting as lead manager for the offering.

You May Also Be Interested In

• CoVolt Power files for proposed IPO
• MAIA Biotechnology (MAIA) files $150M mixed shelf
• Singularity Future Technology closes $5M registered direct offering